TP53 and hepatocellular carcinoma: The compound has been reported to show cytotoxicity against several human tumour cell lines in preliminary screening experiments and has been reported to inhibit lung carcinoma cell proliferation [38], bone metastatic breast cancer [39], and hepatocellular carcinoma cell proliferation by targeting MAPK and TP53 [6, 7, 38, 40].